Latest News

AstraZeneca has advanced its oral weight loss drug elecoglipron into Phase III trials after meeting key Phase II targets. The FDA has granted Priority Review to cancer drug DATROWAY for triple negative breast cancer. Imfinzi has received a positive recommendation in Europe for approval in early stage gastric cancer. AstraZeneca, LSE:AZN, is pushing ahead on several fronts at once, with fresh momentum in obesity and oncology. The shares most recently closed at £148.18, and the stock is up...

Banca Profilo (BIT:PRO) has wrapped up FY 2025 with fourth quarter total revenue of €13.7 million and net income of €0.6 million, against a backdrop of earnings that declined on average by 2.4% per year over the past five years but rose 31.8% in the last year. Over recent periods, total revenue has moved between €17.99 million in Q1 2025 and €13.7 million in Q4 2025, while quarterly net income has ranged from a loss of €0.9 million in Q2 2025 to €8.1 million in Q3 2025. This has fed into a...

Why Dish’s Default Matters for American Tower American Tower (AMT) is back in focus after the company disclosed that Dish Wireless missed lease payments, triggering a default under their Strategic Collaboration Agreement and prompting a move to seek court confirmation of Dish’s obligations. The company has said this default is not expected to affect its 2025 financial results, but for you as a shareholder or potential investor it raises fresh questions about counterparty reliability and how...

Critical Metals Corp. recently reported final 2025 assay results from Area B and the Fjord Deposit at its Tanbreez Rare Earths Project in Greenland, confirming extensive near-surface rare earth mineralisation with Total Rare Earth Oxide plus yttrium grades generally between 0.35% and 0.61% and heavy rare earths making up around a quarter of the mix. The program also highlighted consistent by-product levels of metals such as niobium, hafnium and gallium across a 1,750-metre corridor,...

James Hardie Industries (ASX:JHX) has posted Q3 2026 revenue of US$1.2 billion with basic EPS of US$0.12, alongside trailing 12 month EPS of US$0.24 and net income of US$119.1 million that reflect a compressed net margin versus the prior year. Over recent quarters, revenue has moved from US$953.3 million in Q3 2025 to US$971.5 million in Q4 2025, then to US$899.9 million in Q1 2026, US$1.3 billion in Q2 2026 and US$1.2 billion in Q3 2026. Basic EPS shifted from US$0.33 to US$0.10, then...

Applied Materials recently announced that Samsung Electronics will join its US$5.00 billion EPIC Center in Silicon Valley, a large collaborative R&D facility focused on accelerating next-generation semiconductor process and equipment development across advanced logic and memory. By combining this EPIC collaboration model with newly launched tools for 2nm-and-beyond chips, Applied Materials is positioning its equipment at the heart of future AI and energy-efficient computing roadmaps. We’ll...

Why Marvell Technology (MRVL) is on investors’ radar today Marvell Technology (MRVL) continues to draw attention from investors after a mixed share price pattern, with an 8.6% gain over the past week contrasting with weaker returns over the month and the past three months. See our latest analysis for Marvell Technology. That recent 8.6% 7 day share price return comes after weaker 3 month share price performance of 8.2% and a 1 year total shareholder return decline of 24.6%, so near term...

Earnings trigger renewed focus on TOA (TSE:1885) TOA (TSE:1885) has moved into focus after reporting nine month earnings to 31 December 2025, with sales of ¥256,720 million and net income of ¥14,302 million compared with the prior year period. Basic earnings per share from continuing operations came in at ¥183, versus ¥147.73 a year earlier. This gives investors fresh numbers to reassess how the stock’s recent share price performance lines up with underlying results. See our latest analysis...

Banca Monte dei Paschi di Siena (BIT:BMPS) has just posted its FY 2025 numbers, with fourth quarter revenue at €1,760.8 million and basic EPS of €0.44. This caps a trailing twelve month EPS of €1.54 and net income of €2.72 billion. Over the past year, revenue on a trailing basis has moved from €3,567.6 million in 2024 Q4 to €4,560.9 million in 2025 Q4, while quarterly EPS has stepped up from €0.31 in 2024 Q4 to €0.44 in 2025 Q4. This sets the scene for a results season where higher margins...

Telekom Austria FY 2025 earnings snapshot Telekom Austria (WBAG:TKA) has just wrapped up FY 2025 with fourth quarter revenue of about €1.6b and net income of €145m, while revenue over the last 12 months came in at roughly €5.6b alongside net income of €612m. The company has seen quarterly revenue move from €1.44b in Q4 2024 to €1.56b in Q4 2025, with trailing EPS over the last four reported quarters sitting just under €1 on a per share basis. With a trailing net margin of 11%, investors are...

Thule Group FY 2025 Earnings Snapshot Thule Group (OM:THULE) has wrapped up FY 2025 with Q4 revenue of SEK 1.8b and basic EPS of SEK 0.19, alongside trailing twelve month revenue of SEK 10.4b and EPS of SEK 10.33. The company reported quarterly revenue of SEK 2.7b in Q1 2025, SEK 3.4b in Q2, SEK 2.5b in Q3 and SEK 1.8b in Q4, while EPS over the same periods came in at SEK 2.47, SEK 4.75, SEK 2.91 and SEK 0.19. This provides context for investors assessing how margins have developed over the...

Asker Healthcare Group (OM:ASKER) FY 2025 Results Snapshot Asker Healthcare Group (OM:ASKER) has wrapped up FY 2025 with fourth quarter revenue of SEK4.7 billion and basic EPS of 0.34 SEK, setting the tone for how investors assess the full year. Over recent periods, the company has seen quarterly revenue move from SEK4.3 billion and EPS of 0.24 SEK in Q4 2024 to SEK4.7 billion and EPS of 0.34 SEK in Q4 2025. Trailing twelve month EPS came in at 1.25 SEK on revenue of SEK16.8 billion, giving...

FTI Consulting (FCN) has been busy reshaping its senior leadership, with a cluster of February appointments across healthcare, chemicals, business transformation and intellectual property. These changes give investors fresh context for thinking about the stock. See our latest analysis for FTI Consulting. At a share price of US$173.36, FTI Consulting has seen a 4.8% 90 day share price return and a 1.8% year to date share price return, while the 1 year total shareholder return of 10.2% decline...

Arhaus stock at a glance Arhaus (ARHS) has attracted investor attention after a mixed stretch, with a 15% gain over the past 3 months contrasting with weaker one year and year to date returns at recent prices near US$10.67. See our latest analysis for Arhaus. Recent trading has been choppy, with a 14.9% 90 day share price return contrasting with weaker year to date share price performance and a 14.8% decline in the 1 year total shareholder return. This suggests that momentum has faded after...

The Walt Disney Company ( NYSE:DIS ) announced strong profits, but the stock was stagnant. We did some digging, and we...

If you are wondering whether International Flavors & Fragrances is offering fair value right now, you are not alone. A closer look at its valuation can help frame your next move. The stock last closed at US$76.76, with recent returns of 9.1% over 7 days, 11.1% over 30 days, 12.8% year to date, but a 7.8% decline over 1 year, a 13.2% decline over 3 years and a 35.9% decline over 5 years. These mixed returns leave many investors looking to recent company updates and sector news to understand...

AGM decisions and restructuring set the tone for thyssenkrupp shares Thyssenkrupp (XTRA:TKA) is back in focus after its recent annual general meeting, where shareholders backed all proposals, including continued restructuring and plans for a separate listing of the TKMS defence business. See our latest analysis for thyssenkrupp. The recent AGM decisions come after a strong run in the shares, with the latest share price at €12.22 and a 90 day share price return of 29.01%. The 1 year total...

Alimak Group (OM:ALIG) has wrapped up FY 2025 with fourth quarter revenue of SEK 1,692 million and basic EPS of SEK 0.98, setting the tone for how investors will parse the full year. The company has seen quarterly revenue move between SEK 1,658 million and SEK 1,791 million through 2025, with EPS ranging from SEK 0.98 to SEK 1.74. Trailing twelve month EPS for the period ended Q4 2025 is SEK 5.71. With trailing net margin at 9.9% and recent earnings growth in the backdrop, this latest print...

In recent months, IonQ has reported very large year-over-year revenue growth, pursued multi-billion-dollar acquisitions to build a vertically integrated quantum platform, and faced critical short-seller reports questioning its government-heavy revenue mix and aggressive expansion. Amid this tension between rapid expansion and concerns over cash burn and dilution, IonQ’s attempt to consolidate quantum hardware, networking, sensing, and security into one stack has become a central point of...

Cytokinetics recently announced recipients of its eighth annual Communications Grant Program, awarding two grants to hypertrophic cardiomyopathy patient advocacy groups to expand education and awareness, alongside confirming that MYQORZO (aficamten) is approved for symptomatic obstructive HCM and under marketing review in the European Union. This combination of regulatory progress for MYQORZO and direct support for HCM community outreach highlights how the company is tying its commercial...

What Harmony Biosciences’ Recent Performance Tells Investors Harmony Biosciences Holdings (HRMY) has seen mixed share performance recently, with a modest gain over the past 3 months and a small decline over the past month, prompting investors to reassess the stock. See our latest analysis for Harmony Biosciences Holdings. At a share price of $37.93, Harmony Biosciences’ 90 day share price return of 13.09% contrasts with a 3 year total shareholder return decline of 19.37%, suggesting recent...

Trip.com Group (TCOM) is under investigation by China’s market regulator for potential antitrust violations, a development that has drawn securities class action interest and brought sharp focus to the stock’s recent performance. See our latest analysis for Trip.com Group. The regulatory probe and class action interest have coincided with a 24.0% 1 month share price decline and a weaker year to date share price return of 22.8%, even though the 3 year total shareholder return of 52.9%...

First Financial Bankshares (NasdaqGS:FFIN) has appointed David Bailey as Chief Executive Officer and President. Long-time leader F. Scott Dueser is transitioning to the role of Executive Chairman after many years in top executive positions. The leadership changes mark a new chapter for the company while keeping both executives in key roles. First Financial Bankshares, a regional banking group, sits in a sector that continues to see pressure around funding costs, loan growth, and regulation...

Redbreast, part of Pernod Ricard’s Irish whiskey portfolio, has introduced the Redbreast Moscatel Wine Cask Edition. This limited-edition release is finished in Moscatel wine casks sourced from Spain. The launch highlights Pernod Ricard (ENXTPA:RI) and its focus on premium and specialty cask whiskeys. Pernod Ricard, through Redbreast, is leaning further into premium Irish whiskey with a release built around Moscatel wine casks from Spain. For investors watching ENXTPA:RI, this kind of small...